No recurrence of pneumocystis jirovecii pneumonia after solid organ transplantation regardless of secondary prophylaxis

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 6041-6043

  Kim, Tark ^a   Sung, Heungsup ^a   Lee, Yu Mi ^a   Hong, Hyo Lim ^a   Kim, Sung Han ^a   Choi, Sang Ho ^a   Woo, Jun Hee ^a   Kim, Yang Soo ^a   Lee, Sang Oh ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOSPORIN; DAPSONE; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; FOLLOW UP; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RETROSPECTIVE STUDY; SECONDARY PREVENTION;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RECURRENCE; RETROSPECTIVE STUDIES; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84868007818     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00998-12     Document Type: Article

References (16)

1. Azevedo LS, Castro MC, Paula FJ, Ianhez LE, David-Neto E. 2005. Mycophenolate mofetil may protect against Pneumocystis carinii pneumonia in renal transplanted patients. Rev. Inst. Med. Trop. Sao Paulo 47:143-145.
2. Eitner F, et al. 2011. Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol. Dial. Transplant. 26:2013-2017.
3. Gordon SM, et al. 1999. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin. Infect. Dis. 28:240-246.
4. Kaplan JE, et al. 2009. Guidelines for prevention and treatment of opportunistic infectionsin HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. Rep. 58(RR-4):1-207; quiz CE1-CE4.
5. Kaplan JE, et al. 2000. Epidemiology of human immunodeficiency virus-associated opportunistic infections inthe United States in the era ofhighly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl 1):S5-S14.
6. Lopez Bernaldo de Quiros JC, et al. 2001. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumo-cystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. N. Engl. J. Med. 344:159-167.
7. Lufft V, et al. 1996. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 62:421-423.
8. Martin SI, Fishman JA. 2009. Pneumocystis pneumonia in solid organ transplant recipients. Am. J. Transplant. 9(Suppl 4):S227-S233.
9. Montaner JS, et al. 1991. Aerosol pentamidine for secondary prophylaxis of AIDS-related Pneumocystis carinii pneumonia. A randomized, placebo-controlled study. Ann. Intern. Med. 114:948-953.
10. Mussini C, et al. 2003. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group. Clin. Infect. Dis. 36:645-651.
11. Oz HS, Hughes WT. 1997. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J. Infect. Dis. 175: 901-904.
12. Pfaller MA. Anaissie EJ. Pneumocystis, p 385-401. In Anaissie EJ, McGinnis MR, Pfaller MA (ed), Clinical mycology, 2nd ed. Churchill Livingstone, Oxford, United Kingdom.
13. Radisic M, et al. 2003. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl. Infect. Dis. 5:84-93.
14. Sepkowitz KA. 2002. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin. Infect. Dis. 34:1098-1107.
15. Thomas CF, Jr, Limper AH. 2004. Pneumocystis pneumonia. N. Engl. J. Med. 350:2487-2498.
16. Walmsley S, et al. 1995. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneu-mocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 8:348-357.